Literature DB >> 10478579

Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome.

I Reuter1, C M Ellis, K Ray Chaudhuri.   

Abstract

OBJECTIVES: Nocturnal disabilities leading to fragmented sleep arising from parkinsonian off period related complications are common, under-reported and are difficult to treat. In this study, we evaluate the use of nocturnal continuous subcutaneous overnight apomorphine infusion in Parkinson's disease and restless legs syndrome.
METHODS: Six parkinsonian patients and 2 patients with restless legs syndrome with nocturnal disabilities refractory to conventional oral therapy were assessed using a sleep diary while on standard treatment and during nocturnal apomorphine infusion. Three patients agreed to assessments during placebo infusion with normal saline.
RESULTS: Apomorphine led to a dramatic reduction of nocturnal awakenings, nocturnal off periods, pain, dystonia and nocturia in parkinsonian patients. In patients with restless legs syndrome, apomorphine reduced nocturnal discomfort, reduced leg movements and improved pain and spasm scores significantly. Placebo infusion reproduced pain, nocturnal spasms and sleep disruption.
CONCLUSION: This study suggests that overnight apomorphine infusion may be effective in overcoming refractory nocturnal disabilities in selected patients with Parkinson's disease and restless legs syndrome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10478579     DOI: 10.1111/j.1600-0404.1999.tb00732.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  29 in total

1.  The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease.

Authors:  K R Chaudhuri; S Pal; A DiMarco; C Whately-Smith; K Bridgman; R Mathew; F R Pezzela; A Forbes; B Högl; C Trenkwalder
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

Review 2.  Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Authors:  Svenja Happe; Claudia Trenkwalder
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?

Authors:  Rupam Borgohain; Rukmini Mridula Kandadai; Afshan Jabeen; Meena A Kannikannan
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

Review 4.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

5.  Treatment of restless legs syndrome with subcutaneous apomorphine in a patient with short bowel syndrome.

Authors:  T Tings; G Stiens; W Paulus; C Trenkwalder; S Happe
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

6.  Continuous Subcutaneous Apomorphine Infusion Improves Severe Restless Legs Syndrome.

Authors:  Thomas Müller; Marion Marg; Hartmut Rothe; Matthias Küchler
Journal:  Mov Disord Clin Pract       Date:  2014-06-04

Review 7.  Therapies for Restless Legs in Parkinson's Disease.

Authors:  Valérie Cochen De Cock
Journal:  Curr Treat Options Neurol       Date:  2019-11-09       Impact factor: 3.598

8.  Restless legs syndrome: pathophysiology and treatment.

Authors:  William G Ondo
Journal:  Curr Treat Options Neurol       Date:  2014-11       Impact factor: 3.598

9.  Treatment of sleep disorders in elderly patients.

Authors:  John J Harrington; Alon Y Avidan
Journal:  Curr Treat Options Neurol       Date:  2005-09       Impact factor: 3.598

10.  Restless legs syndrome: diagnosis and review of management options.

Authors:  Ruth Byrne; Smita Sinha; K Ray Chaudhuri
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.